ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess™ (RelabotulinumtoxinA - previously referred to as QM1114). Relfydess™ is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.[9] Following the successful completion of the DCP, national approvals in the 16 concerned countries are now under finalization. Relfydess™ also received a marketing authorization in Australia earlier this year.

Relfydess™ is developed and manufactured by Galderma. It is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow’s feet.[3,4,7,8] It is optimized for simple volumetric dosing, without reconstitution, to increase ease of use and help ensure consistent dose/volume.[1,10]

“With Relfydess™, Galderma is introducing a highly differentiated and innovative neuromodulator, reinforcing our leadership and strong growth in this field, and our commitment to developing and delivering the broadest portfolio in Injectable Aesthetics. As per the decentralized European approach, our teams are now finalizing the approval procedures at the country level, so we’re ready to launch in multiple markets early next year.” FLEMMING ØRNSKOV, M.D., MPH, CHIEF EXECUTIVE OFFICER GALDERMA

This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants. Results showed:[3,4,7,8]

· Improvement in both frown lines and crow’s feet versus placebo:
- In READY-1 and READY-2, treatment with Relfydess™ demonstrated a 96.3% none-or-mild responder rate for frown lines and 87.2% for crow’s feet, after one month, vs 4.5% and 11.9% for placebo, respectively.

· Onset of action as soon as day one:
- In READY-1 and READY-2, 39% of patients reported improvements for frown lines and 34% reported improvements for crow’s feet from day one.

· Sustained results for six months:
- In READY-1 and READY-2, up to 75% of patients maintained improvements for six months.
- At month one, up to 96% achieved none-or-mild frown lines and crow’s feet, which was sustained for six months in almost a quarter of patients.

· Patient satisfaction was maintained for six months following treatment.

“With the growing need for new innovations in the neuromodulator space, I’m excited that, with Relfydess™, we have a new treatment that delivers both fast and sustained results in a simple and convenient formulation, so we can achieve the desired outcomes for our patients quickly, effectively, and without compromise.” DR. SACHIN SHRIDHARANI LEAD INVESTIGATOR OF READY-1 TRIAL PLASTIC SURGEON AND FOUNDER OF LUXURGERY

Regulatory applications for Relfydess™ for the treatment of frown lines and crow’s feet will continue to be submitted and assessed by additional authorities globally.

About Relfydess™ (RelabotulinumtoxinA)

Pioneered by Galderma, Relfydess™ is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity.[1,2] PEARL™ Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.[1-4,7,8] Relfydess™ is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.[1,10] It was entirely developed and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.

About the READY clinical trial program

The READY (RElabotulinumtoxin Aesthetic Development StudY) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.3-6 The READY trials investigated the safety, efficacy, rapidity of onset and/or durability of Relfydess™ for six months on:

· Frown lines (READY-1).[3]
· Crow’s feet (READY-2).[4]
· Frown lines and crow’s feet when treated alone or simultaneously (READY-3).[5]
· Frown lines and crow’s feet when treated alone or simultaneously with up to four repeated injections over 52 weeks (READY-4).[6]

About Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

[1] Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting
[2] Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA
[3] Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021
[4] Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021
[5] Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021
[6] Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021
[7] Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. Aesthetic Surgery Journal. 2024; sjae131
[8] Ablon G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin
[9] Relfydess® EU Summary of Product Characteristics
[10] Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729848736/en/

Website: http://www.galderma.com Contact Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 76 315 26 50
[email protected]

Sébastien Cros
Corporate Communications Director
+41 79 529 59 85
[email protected]

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
+41 21 642 78 12
[email protected]

Jessica Cohen
Investor Relations and Strategy Director
+41 21 642 76 43
[email protected]
This news is a press release provided by Galderma. Korea Newswire follows these editorial guidelines. Galderma News ReleasesSubscribeRSS Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024. · Record net sales of 2.2 billion USD in the first half of 2024, with net sales growth of 10.8% on a constant currency basis[1], predominantly driven by volume... 7월 25일 17:25 PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis - Itch, Skin Lesions and Sleep Disturbance Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet .[1]The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without t... 7월 25일 15:31 ... More  More News Health Clinical Trials Pharmaceutical R&D Overseas Galderma All News Releases 